Business
DECN Announces Market Readiness of Its GenUltimate TBG, Adds To Product's Compatibility at The Request Of Strategic Partner, Completes Its Universal Translator GenExpidient! Device
DECN Announces Market Readiness of Its GenUltimate TBG, Adds To Product's Compatibility at The Request Of Strategic Partner, Completes Its Universal Translator GenExpidient! Device.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Company posts initial forecast for its new GenAccord!, moves two new products GenUltimate! precis TBG and GenCambre! into advanced development, readies patents for GenUltimate TBG & GenExpidient!LOS ANGELES, CA / ACCESSWIRE / February 20, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, its mate! GenUltimate Precis products manufactured for Eastern European International markets. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. Finally the company has certified as market ready its GenUltimate! TBG ("Dragonfly") diabetes testing system, and announces the completion of its Universal Translator device GenExpidient!, a device that serves as a universal translation device and dramatically speeds development of alternative test strips that will run on legacy systems.The company also announced that with the completion of development of the GenExpiedient! Universal Translator, two products in development have been moved to Advanced Development (approx. 120 days to commercial viability), GenCambre! and the TBG version of GenUltimate! Precis TBG. Precis TBG will sell through our Russian Federation partner. Keith Berman, CEO of Decision Diagnostics stated "Despite our limited resources, or perhaps because we have fewer resources, we have been able to channel our activities into products that can be introduced to the market quickly. In 2020 we will have introduced GenUltimate! TBG, GenAccord!, GenCambre! and now GenExpidient! " Mr. Berman continued, "We have great hopes for GenExpidient! This device that will allow similar commercial systems with different glucometers and/or meters of different vintage to work with the same test strip of our development. This has brought an...